823 results on '"De Vita F"'
Search Results
202. Use of proton pump inhibitors is associated with lower trabecular bone mineral density in older individuals
203. The role of university-territory platform in the screening of physical frailty in community-dwelling older adult: Data from MED&SANO study
204. Insulin-like Growth Factor (IGF)-1 bioactivity plays a pro-survival role in older subjects
205. Serum Insulin-Like Growth Factor 1 Correlates with the Risk of Nodal Metastasis in Endocrine-Positive Breast Cancer
206. Insulin-Like Growth Factor-1 Bioactivity Plays a Prosurvival Role in Older Participants
207. P.11.21 SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH A OR B CIRRHOSIS
208. The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older persons
209. Overview of the software integration activities within ACE
210. Use of proton pump inhibitors and insulin like growth factor-1 system in older subjects
211. Natural History of Bone Metastasis in Gastric Cancer: Results of an Italian Multicenter Survey
212. PP032-MON RELATIONSHIP BETWEEN USE OF PROTON PUMP INHIBITORS AND IGF SYSTEM IN OLDER SUBJECTS: THE InCHIANTI STUDY
213. Targeting EGFR in Pancreatic Cancer Treatment
214. Pharmacoeconomic considerations on treatment of multiple sclerosis: importance of computerisation and role of the daily dose received
215. Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials
216. Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell'Italia Meridionale.
217. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
218. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
219. Update on capecitabine alone and in combination regimens in colorectal cancer patients
220. Maintenance therapy in colon cancer
221. Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT).
222. A rare case of extraovarian primary peritoneal carcinoma in a 72 year-old woman
223. Performances of MR-preconditioned fast MoM techniques
224. Ischiatic pressure sores: our experience in coupling a split-muscle flap and a fasciocutaneous flap in a ‘criss-cross’ way
225. 6565 The role of PET-TC in predicting the pCR in locally-advanced esophageal cancer (LAEC) after a preoperative CT-RT treatment: data from B152 trial
226. 6550 Adjuvant chemoradiation in stage III-IV radically resected gastric cancer patients: a pilot study
227. 6566 A multicenter phase II study of induction CT with Folfox-4 and Cetuximab followed by RT and Cetuximab in locally advanced esophageal cancer (LAEC)
228. 1223 A model of synergistic antitumour activity of sorafenib, a multikinase inhibitor of Raf, VEGF and PDGF receptors, with anti-EGFR inhibitors (cetuximab and erlotinib) in a panel of colorectal and lung cancer cell lines
229. 1221 Enhanced sensitivity to Bortezomib pro apoptotic effects in human cancer cells with acquired resistance to anti-EGFR TKIs
230. A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC)
231. FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)
232. An Efficient Technique for the Analysis of Large Multilayered Printed Arrays
233. Bevacizumab+folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2601)
234. Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405)
235. Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): Analysis of preliminary data from B152 Trial
236. Bevacizumab + folfiri as first-line treatment in advanced colorectal cancer (ACC): A multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2601)
237. Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer
238. An efficient technique for the analysis of reflectarrays
239. Fast analysis of large finite arrays with a combined multiresolution-fast MoM based techniques
240. Overview of the software integration activities within ACE
241. Efficient Green's function factorization for the analysis of large patch antennas on multilayered media with the SM/AIM method
242. Surgery plus ELFE (epirubicin, leucovorin, 5-fluorouracil and etoposide) vs surgery alone in radically resected gastric cancer (GC): Final results of a randomised phase III trial by the Gruppo Oncologico dell’ Italia Meridionale (GOIM)
243. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
244. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
245. Phase II study of weekly docetaxel and capecitabine in patients with metastatic gastric cancer (GC)
246. Phase II trial of gefitinib combined with docetaxel as first-line therapy in patients with metastatic breast cancer
247. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
248. Factorization of stratified Green's function
249. A time-domain raw signal Simulator for interferometric SAR
250. Oxaliplatin (OXA) plus folinic acid (FA) and 5-fluorouracil (FU) i.v. bolus (OXAFAFU) versus irinotecan (IRI) plus FA and FU i.v. bolus (IRIFAFU) in advanced colorectal carcinoma (ACC): Activity and toxicity results of the SICOG 0103 randomized trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.